SALT LAKE CITY, June 23 /PRNewswire-FirstCall/ -- Results from a phase II study presented this week demonstrated the effects of VEC-162 in a model of transient insomnia on the traditional measures of sleep onset and maintenance. VEC-162, an investigational agent under clinical development by Vanda Pharmaceuticals for the treatment of insomnia, is a novel melatonin agonist. The data were presented at the SLEEP 20th Anniversary Meeting of the Associated Professional Sleep Societies (APSS) by Dr. Shantha M.W. Rajaratnam, Division of Sleep Medicine, Brigham and Women’s Hospital, Harvard Medical School.
